Abivax SA
ABVX70.415USD
-1.530-2.13%
Market hours （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Abivax SA Company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
Ticker SymbolABVX
Company nameAbivax SA
IPO dateJun 26, 2015
CEOMr. Marc De Garidel
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address7-11 Boulevard Haussmann
CityPARIS
Stock exchangeEuronext Paris
CountryFrance
Postal code75009
Phone33153830963
Websitehttps://www.abivax.com/
Ticker SymbolABVX
IPO dateJun 26, 2015
CEOMr. Marc De Garidel
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Patrick Malloy
Mr. Patrick Malloy
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Michael Ferguson
Mr. Michael Ferguson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Board Secretary
Chief Financial Officer, Board Secretary
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Dr. Fabio Cataldi, M.D.
Dr. Fabio Cataldi, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Ana Sharma
Ms. Ana Sharma
Vice President - Global Head of Quality
Vice President - Global Head of Quality
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Patrick Malloy
Mr. Patrick Malloy
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Michael Ferguson
Mr. Michael Ferguson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Board Secretary
Chief Financial Officer, Board Secretary
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Dr. Fabio Cataldi, M.D.
Dr. Fabio Cataldi, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, May 18
Updated: Sun, May 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.86%
Adar1 Capital Management LLC
3.00%
Cormorant Asset Management, LP
2.90%
Great Point Partners, LLC
2.23%
Other
78.78%
Shareholders
Shareholders
Proportion
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.86%
Adar1 Capital Management LLC
3.00%
Cormorant Asset Management, LP
2.90%
Great Point Partners, LLC
2.23%
Other
78.78%
Shareholder Types
Shareholders
Proportion
Hedge Fund
23.84%
Investment Advisor
10.96%
Investment Advisor/Hedge Fund
3.77%
Venture Capital
2.49%
Research Firm
2.19%
Other
56.74%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
74
31.84M
43.27%
-317.18K
2025Q1
74
31.82M
50.18%
-39.44K
2024Q4
67
29.91M
47.53%
+1.67M
2024Q3
53
27.43M
43.59%
-1.47M
2024Q2
50
28.12M
44.69%
-980.96K
2024Q1
45
23.37M
37.15%
+1.78M
2023Q4
32
21.64M
34.39%
+20.54M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
TCG Crossover Management, LLC
6.06M
9.55%
--
--
Mar 31, 2025
Deep Track Capital LP
3.58M
5.64%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
2.21M
3.48%
+696.63K
+46.03%
Mar 31, 2025
Cormorant Asset Management, LP
2.13M
3.36%
--
--
Mar 31, 2025
Great Point Partners, LLC
1.64M
2.58%
-10.41K
-0.63%
Mar 31, 2025
Nantahala Capital Management, LLC
1.48M
2.34%
+46.95K
+3.27%
Mar 31, 2025
Citadel Advisors LLC
1.37M
2.17%
+518.18K
+60.56%
Mar 31, 2025
Franklin Advisers, Inc.
1.37M
2.16%
-95.01K
-6.48%
Mar 31, 2025
VR Adviser, LLC
1.35M
2.12%
--
--
Mar 31, 2025
Caligan Partners, LP
1.27M
2%
+516.95K
+68.73%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Innovator IBD Breakout Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
